Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer.

Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Vénissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P.

Br J Cancer. 2014 Mar 4;110(5):1236-43. doi: 10.1038/bjc.2014.11. Epub 2014 Jan 28.

2.

Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome.

Najjar F, Alammar M, Bachour M, Al-Massarani G.

Int J Biol Markers. 2014 Dec 9;29(4):e337-44. doi: 10.5301/jbm.5000100.

PMID:
25041783
3.

Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD.

Kratzer A, Chu HW, Salys J, Moumen Z, Leberl M, Bowler R, Cool C, Zamora M, Taraseviciene-Stewart L.

J Pathol. 2013 Aug;230(4):388-98. doi: 10.1002/path.4197.

PMID:
23649916
4.

Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.

Yuan DM, Zhang Q, Lv YL, Ma XQ, Zhang Y, Liu HB, Song Y.

Tumour Biol. 2015 Nov;36(11):9031-7. doi: 10.1007/s13277-015-3657-y. Epub 2015 Jun 18.

PMID:
26084612
5.

Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.

Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N.

Eur J Cardiothorac Surg. 2007 Sep;32(3):435-9. Epub 2007 Jul 3.

PMID:
17611117
6.

Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients.

Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ, Toi M.

Eur J Cancer. 2011 Oct;47(15):2265-72. doi: 10.1016/j.ejca.2011.06.015. Epub 2011 Jul 5.

PMID:
21737256
7.

Baseline and post-surgery endothelial progenitor cell levels in patients with early-stage non-small-cell lung carcinoma: impact on cancer recurrence and survival.

Pirro M, Cagini L, Paciullo F, Pecoriello R, Mannarino MR, Bagaglia F, Capozzi R, Puma F, Mannarino E.

Eur J Cardiothorac Surg. 2013 Oct;44(4):e245-52. doi: 10.1093/ejcts/ezt382. Epub 2013 Jul 23.

PMID:
23882070
8.

Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer.

Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J.

Cancer Res. 2006 Jul 15;66(14):7341-7.

9.

Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.

Hu Y, Hu MM, Shi GL, Han Y, Li BL.

Eur J Surg Oncol. 2014 Sep;40(9):1136-42. doi: 10.1016/j.ejso.2014.05.014. Epub 2014 Jun 26.

10.

Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer.

Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M, Gómez-Codina J, Montalar J, Reynés G.

PLoS One. 2012;7(10):e47365. doi: 10.1371/journal.pone.0047365. Epub 2012 Oct 15.

11.

Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.

Suzuki H, Ishikawa S, Satoh H, Ishikawa H, Sakai M, Yamamoto T, Onizuka M, Sakakibara Y.

Eur J Cardiothorac Surg. 2007 Oct;32(4):648-52. Epub 2007 Aug 17.

PMID:
17707649
12.

Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer.

Cao YT, Li JH, Wang YT, Fu YW, Xu J.

Tumori. 2014 Mar-Apr;100(2):214-8. doi: 10.1700/1491.16419.

PMID:
24852868
13.

On the origin of (CD105+) circulating endothelial cells.

Strijbos MH, Verhoef C, Gratama JW, Sleijfer S.

Thromb Haemost. 2009 Aug;102(2):347-51. doi: 10.1160/TH08-11-0762.

PMID:
19652886
14.

[Correlation between baseline plasma D-dimer levels and prognosis in patients with non-smal cell lung cancer].

Zhang PP, Sun JW, Lu JQ, Ma LL, Li K.

Zhonghua Zhong Liu Za Zhi. 2013 Oct;35(10):747-50. Chinese.

PMID:
24378095
15.

[Circulating endothelial cells in the peripheral blood of advanced NSCLC patients].

Huang C, Li K, Wei XY, Niu RF, Sun Y, Wang JW, Zhu YZ, Xu LY, Liu XQ, Gao HJ, Zhou JM, Wang XW.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):780-3. Chinese.

PMID:
17366796
16.

Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen.

Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y, Zhang J, Luo Y, Zhang L, Zheng S, Zhou Q, Li H, Liu Y, Qu X.

BMC Cancer. 2012 Aug 1;12:330. doi: 10.1186/1471-2407-12-330.

17.

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ.

Br J Cancer. 2012 Mar 13;106(6):1153-9. doi: 10.1038/bjc.2012.50. Epub 2012 Feb 21.

18.

Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.

Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Yamada S, Tanaka F.

Clin Lung Cancer. 2013 May;14(3):288-94. doi: 10.1016/j.cllc.2012.09.005. Epub 2012 Nov 1.

PMID:
23122494
19.

Circulating endothelial cells in coronary artery disease.

Lampka M, Grąbczewska Z, Jendryczka-Maćkiewicz E, Hołyńska-Iwan I, Sukiennik A, Kubica J, Halota W, Tyrakowski T.

Kardiol Pol. 2010 Oct;68(10):1100-5.

20.

Hematogenous dissemination of lung cancer cells during surgery: quantitative detection by flow cytometry and prognostic significance.

Dong Q, Huang J, Zhou Y, Li L, Bao G, Feng J, Sha H.

Lung Cancer. 2002 Sep;37(3):293-301.

PMID:
12234699
Items per page

Supplemental Content

Write to the Help Desk